Equity Profile

HOLX

Hologic, Inc.

Health CareHealth Care Equipment

May1Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Hologic, Inc. is a health care company that focuses on developing innovative medical devices and diagnostics, primarily in women's health....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Hologic is managing its costs and generating profit.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand and capture market share in the health care sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

HOLX Q2-2026 Earnings Preview

Context

Company Snapshot

Hologic, Inc. is a health care company that focuses on developing innovative medical devices and diagnostics, primarily in women's health. With a strong presence in the health care equipment sector, Hologic plays a crucial role in providing essential health solutions, particularly in areas like breast health and diagnostics.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-1.56%

Avg Stock Reaction

+0.13%

Last Quarter Recap

In Q1-2026, Hologic reported an EPS of $1.04, which was slightly below the expected $1.09, resulting in a 4.5% earnings surprise. The stock experienced a minor decline of 0.16% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street appears cautious ahead of Hologic's earnings report, especially given the recent EPS miss. Investors are closely watching for signs of recovery in revenue and profitability.

Bull Case

If Hologic can demonstrate strong revenue growth and improved margins, it could signal a turnaround, boosting investor confidence and stock performance.

Bear Case

Conversely, if the company reports another earnings miss or weak guidance, it may raise concerns about its growth prospects and lead to further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be crucial for assessing the company's profitability and whether it can meet or exceed market expectations.

How is Hologic addressing recent revenue challenges?

Understanding management's strategy for revenue growth will be key to evaluating the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Hologic's potential for a rebound in demand, particularly in women's health products, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

Historical data shows a 75% EPS beat rate, suggesting Hologic often exceeds expectations.

Options pricing indicates a significant move, reflecting uncertainty that could favor a positive surprise.

The recent decline in stock price may have already priced in negative sentiment, leaving room for a rebound.

Key Risk

If the company reports revenue growth above 10%, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's debate centers around Hologic's ability to recover from recent earnings misses and demonstrate sustainable growth.

Bull Confirmed If

A revenue growth rate of 10% or higher would confirm the bull case and suggest strong demand for Hologic's products.

Bear Confirmed If

A decline in gross margin below 55% would confirm the bear case and raise concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±40.8%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a significant move of approximately 40.8%, indicating heightened uncertainty or expectations for volatility around the earnings report.

Options are pricing ±40.8% while HOLX has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

30d HV

2.7%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Hologic beats expectations, history suggests the stock could see a modest increase, confirming a positive outlook for growth.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious management commentary could lead to volatility.

Miss

If Hologic misses again, history suggests a potential decline in stock price, reflecting ongoing concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in women's health.
2Insights into cost management strategies and their impact on margins.
3Details on market demand trends for diagnostic equipment.
4Management's outlook on future revenue growth and profitability.
5Responses to competitive pressures in the health care equipment sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Moelis & Company

Company Snapshot

Hologic, Inc. is a health care company that focuses on developing innovative medical devices and diagnostics, primarily in women's health....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Hologic is managing its costs and generating profit.

N/A

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand and capture market share in the health care sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

HOLX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-1.56%

Avg Stock Reaction

+0.13%

Last Quarter Recap

In Q1-2026, Hologic reported an EPS of $1.04, which was slightly below the expected $1.09, resulting in a 4.5% earnings surprise. The stock experienced a minor decline of 0.16% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street appears cautious ahead of Hologic's earnings report, especially given the recent EPS miss. Investors are closely watching for signs of recovery in revenue and profitability.

Bull Case

If Hologic can demonstrate strong revenue growth and improved margins, it could signal a turnaround, boosting investor confidence and stock performance.

Bear Case

Conversely, if the company reports another earnings miss or weak guidance, it may raise concerns about its growth prospects and lead to further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be crucial for assessing the company's profitability and whether it can meet or exceed market expectations.

How is Hologic addressing recent revenue challenges?

Understanding management's strategy for revenue growth will be key to evaluating the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Hologic's potential for a rebound in demand, particularly in women's health products, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

Historical data shows a 75% EPS beat rate, suggesting Hologic often exceeds expectations.

Options pricing indicates a significant move, reflecting uncertainty that could favor a positive surprise.

The recent decline in stock price may have already priced in negative sentiment, leaving room for a rebound.

Key Risk

If the company reports revenue growth above 10%, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's debate centers around Hologic's ability to recover from recent earnings misses and demonstrate sustainable growth.

Bull Confirmed If

A revenue growth rate of 10% or higher would confirm the bull case and suggest strong demand for Hologic's products.

Bear Confirmed If

A decline in gross margin below 55% would confirm the bear case and raise concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±40.8%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a significant move of approximately 40.8%, indicating heightened uncertainty or expectations for volatility around the earnings report.

Options are pricing ±40.8% while HOLX has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

30d HV

2.7%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Hologic beats expectations, history suggests the stock could see a modest increase, confirming a positive outlook for growth.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious management commentary could lead to volatility.

Miss

If Hologic misses again, history suggests a potential decline in stock price, reflecting ongoing concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in women's health.
2Insights into cost management strategies and their impact on margins.
3Details on market demand trends for diagnostic equipment.
4Management's outlook on future revenue growth and profitability.
5Responses to competitive pressures in the health care equipment sector.